{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:41:28Z","timestamp":1785768088966,"version":"3.56.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T00:00:00Z","timestamp":1727481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T00:00:00Z","timestamp":1727481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s10787-024-01567-z","type":"journal-article","created":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T07:02:05Z","timestamp":1727506925000},"page":"3729-3738","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Repurposing celecoxib as adjuvant therapy in patients with Parkinsonian disease: a new therapeutic dawn: randomized controlled pilot study"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0489-1579","authenticated-orcid":false,"given":"Mohannad O.","family":"Khrieba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar K.","family":"Hegazy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wessam","family":"Mustafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar M.","family":"El\u2011Haggar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,28]]},"reference":[{"issue":"1","key":"1567_CR1","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0896-6273(00)80886-7","volume":"25","author":"A Abeliovich","year":"2000","unstructured":"Abeliovich A, Schmitz Y, Fari\u00f1as I et al (2000) Mice lacking \u03b1-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25(1):239\u2013252","journal-title":"Neuron"},{"key":"1567_CR2","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.2147\/DDDT.S207310","volume":"13","author":"LT Al Kury","year":"2019","unstructured":"Al Kury LT, Zeb A, Abidin ZU et al (2019) Neuroprotective effects of melatonin and celecoxib against ethanol-induced neurodegeneration: a computational and pharmacological approach. Drug Des Dev Ther 13:2715\u20132727","journal-title":"Drug Des Dev Ther"},{"key":"1567_CR3","doi-asserted-by":"publisher","first-page":"102143","DOI":"10.1016\/j.arr.2023.102143","volume":"93","author":"HM Al-Kuraishy","year":"2023","unstructured":"Al-Kuraishy HM, Al-Gareeb AI, Alexiou A et al (2023) Calprotectin in Parkinsonian disease: anticipation and dedication. Ageing Res Rev 93:102143","journal-title":"Ageing Res Rev"},{"issue":"1","key":"1567_CR4","doi-asserted-by":"publisher","first-page":"6271","DOI":"10.1038\/s41598-018-24548-z","volume":"8","author":"F Al-Rashed","year":"2018","unstructured":"Al-Rashed F, Calay D, Lang M et al (2018) Celecoxib exerts protective effects in the vascular endothelium via COX-2-independent activation of AMPK-CREB-Nrf2 signalling. Sci Rep 8(1):6271","journal-title":"Sci Rep"},{"issue":"2","key":"1567_CR5","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s10787-023-01192-2","volume":"31","author":"M Alrouji","year":"2023","unstructured":"Alrouji M, Al-Kuraishy HM, Al-Gareeb AI et al (2023) A story of the potential effect of non-steroidal anti-inflammatory drugs (NSAIDs) in Parkinson\u2019s disease: beneficial or detrimental effects. Inflammopharmacology 31(2):673\u2013688","journal-title":"Inflammopharmacology"},{"issue":"6","key":"1567_CR6","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1046\/j.1471-4159.2001.00205.x","volume":"76","author":"M Asanuma","year":"2001","unstructured":"Asanuma M, Nishibayashi-Asanuma S, Miyazaki I et al (2001) Neuroprotective effects of non-steroidal anti-inflammatory drugs by direct scavenging of nitric oxide radicals. J Neurochem 76(6):1895\u20131904","journal-title":"J Neurochem"},{"key":"1567_CR7","doi-asserted-by":"publisher","first-page":"1434512","DOI":"10.3389\/fphar.2024.1434512","volume":"15","author":"AM Badawoud","year":"2024","unstructured":"Badawoud AM, Ali LS, Abdallah MS, Elsabaa RM, Bahaa MM, Elmasry TA, Wahsh E, Yasser M, Eltantawy N, Eldesoqui M, Hamouda MA  (2024) The relation between Parkinson\u2019s disease and non-steroidal anti-inflammatories; a systematic review and meta-analysis. Front Pharmacol 15:1434512","journal-title":"Front Pharmacol"},{"issue":"5","key":"1567_CR8","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/pca.2616","volume":"27","author":"N Basar","year":"2016","unstructured":"Basar N, Nahar L, Oridupa OA et al (2016) Utilization of the ability to induce activation of the nuclear factor (erythroid-derived 2)-like factor 2 (Nrf2) to assess potential cancer chemopreventive activity of liquorice samples. Phytochem Anal 27(5):233\u2013238","journal-title":"Phytochem Anal"},{"key":"1567_CR9","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00401-009-0522-3","volume":"118","author":"RD Bell","year":"2009","unstructured":"Bell RD, Zlokovic BV (2009) Neurovascular mechanisms and blood\u2013brain barrier disorder in Alzheimer\u2019s disease. Acta Neuropathol 118:103\u2013113","journal-title":"Acta Neuropathol"},{"issue":"49","key":"1567_CR10","doi-asserted-by":"publisher","first-page":"29542","DOI":"10.1074\/jbc.M115.691592","volume":"290","author":"B Butler","year":"2015","unstructured":"Butler B, Saha K, Rana T et al (2015) Dopamine transporter activity is modulated by \u03b1-synuclein. J Biol Chem 290(49):29542\u201329554","journal-title":"J Biol Chem"},{"issue":"3","key":"1567_CR11","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41419-023-05672-9","volume":"14","author":"P Calabresi","year":"2023","unstructured":"Calabresi P, Mechelli A, Natale G et al (2023) Alpha-synuclein in Parkinson\u2019s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. Cell Death Dis 14(3):176","journal-title":"Cell Death Dis"},{"issue":"7","key":"1567_CR12","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3390\/antiox9070597","volume":"9","author":"K-H Chang","year":"2020","unstructured":"Chang K-H, Chen C-M (2020) The role of oxidative stress in Parkinson\u2019s disease. Antioxidants 9(7):597","journal-title":"Antioxidants"},{"issue":"8","key":"1567_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2251","volume":"11","author":"E Chang","year":"2021","unstructured":"Chang E, Wang J (2021) Brain-derived neurotrophic factor attenuates cognitive impairment and motor deficits in a mouse model of Parkinson\u2019s disease. Brain Behav 11(8):e2251","journal-title":"Brain Behav"},{"key":"1567_CR14","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00415-010-5728-8","volume":"257","author":"M Contin","year":"2010","unstructured":"Contin M, Martinelli P (2010) Pharmacokinetics of levodopa. J Neurol 257:253\u2013261","journal-title":"J Neurol"},{"key":"1567_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.108378","volume":"194","author":"S Dassati","year":"2021","unstructured":"Dassati S, Schweigreiter R, Buechner S et al (2021) Celecoxib promotes survival and upregulates the expression of neuroprotective marker genes in two different in vitro models of Parkinson\u2019s disease. Neuropharmacology 194:108378","journal-title":"Neuropharmacology"},{"key":"1567_CR16","doi-asserted-by":"crossref","unstructured":"Derry S, Barden J, McQuay HJ et al. (2008) Single dose oral celecoxib for acute postoperative pain in adults. In: Cochrane database of systematic reviews(4)","DOI":"10.1002\/14651858.CD004233.pub2"},{"issue":"1","key":"1567_CR17","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.brainres.2006.04.013","volume":"1095","author":"V Di Matteo","year":"2006","unstructured":"Di Matteo V, Pierucci M, Di Giovanni G et al (2006) Aspirin protects striatal dopaminergic neurons from neurotoxin-induced degeneration: an in vivo microdialysis study. Brain Res 1095(1):167\u2013177","journal-title":"Brain Res"},{"issue":"4","key":"1567_CR18","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3233\/JPD-130230","volume":"3","author":"V Dias","year":"2013","unstructured":"Dias V, Junn E, Mouradian MM (2013) The role of oxidative stress in Parkinson\u2019s disease. J Parkinsons Dis 3(4):461\u2013491","journal-title":"J Parkinsons Dis"},{"issue":"3","key":"1567_CR19","doi-asserted-by":"publisher","first-page":"167","DOI":"10.4103\/ijabmr.IJABMR_344_19","volume":"10","author":"A Dixit","year":"2020","unstructured":"Dixit A, Pandey P, Dhasmana D (2020) In vivo effects of nonselective, partially selective, and selective non steroidal anti-inflammatory drugs on lipid peroxidation and antioxidant enzymes in patients with rheumatoid arthritis: a clinical study. Int J Appl Basic Med Res 10(3):167\u2013172","journal-title":"Int J Appl Basic Med Res"},{"issue":"2","key":"1567_CR20","first-page":"5","volume":"46","author":"D Dokmeci","year":"2004","unstructured":"Dokmeci D (2004) Ibuprofen and Alzheimer\u2019s disease. Folia Med 46(2):5\u201310","journal-title":"Folia Med"},{"issue":"9","key":"1567_CR21","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/s41582-020-0394-7","volume":"16","author":"I Fyfe","year":"2020","unstructured":"Fyfe I (2020) Aspirin and ibuprofen could lower risk of LRRK2 Parkinson disease. Nat Rev Neurol 16(9):460\u2013460","journal-title":"Nat Rev Neurol"},{"issue":"12","key":"1567_CR22","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1212\/WNL.0b013e3181d5a4a3","volume":"74","author":"JJ Gagne","year":"2010","unstructured":"Gagne JJ, Power MC (2010) Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis. Neurology 74(12):995\u20131002","journal-title":"Neurology"},{"issue":"1","key":"1567_CR23","first-page":"4784268","volume":"2018","author":"G Gelders","year":"2018","unstructured":"Gelders G, Baekelandt V, Van der Perren A (2018) Linking neuroinflammation and neurodegeneration in Parkinson\u2019s disease. J Immunol Res 2018(1):4784268","journal-title":"J Immunol Res"},{"issue":"4","key":"1567_CR24","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/FPC.0b013e32834f94cb","volume":"22","author":"L Gong","year":"2012","unstructured":"Gong L, Thorn CF, Bertagnolli MM et al (2012) Celecoxib pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genom 22(4):310\u2013318","journal-title":"Pharmacogenet Genom"},{"issue":"5291","key":"1567_CR25","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1126\/science.274.5291.1383","volume":"274","author":"M Grilli","year":"1996","unstructured":"Grilli M, Pizzi M, Memo M et al (1996) Neuroprotection by aspirin and sodium salicylate through blockade of NF-\u03baB activation. Science 274(5291):1383\u20131385","journal-title":"Science"},{"issue":"3","key":"1567_CR26","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.neuropharm.2007.11.010","volume":"54","author":"M Hirohata","year":"2008","unstructured":"Hirohata M, Ono K, Morinaga A et al (2008) Non-steroidal anti-inflammatory drugs have potent anti-fibrillogenic and fibril-destabilizing effects for \u03b1-synuclein fibrils in vitro. Neuropharmacology 54(3):620\u2013627","journal-title":"Neuropharmacology"},{"issue":"7","key":"1567_CR27","doi-asserted-by":"publisher","first-page":"756","DOI":"10.3390\/s6070756","volume":"6","author":"X-J Huang","year":"2006","unstructured":"Huang X-J, Choi Y-K, Im H-S et al (2006) Aspartate aminotransferase (AST\/GOT) and alanine aminotransferase (ALT\/GPT) detection techniques. Sensors 6(7):756\u2013782","journal-title":"Sensors"},{"issue":"3","key":"1567_CR28","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1093\/clinchem\/14.3.222","volume":"14","author":"H Husdan","year":"1968","unstructured":"Husdan H, Rapoport A (1968) Estimation of creatinine by the Jaffe reaction: a comparison of three methods. Clin Chem 14(3):222\u2013238","journal-title":"Clin Chem"},{"key":"1567_CR29","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00228-011-1121-5","volume":"68","author":"K Ingman","year":"2012","unstructured":"Ingman K, Naukkarinen T, Vahteristo M et al (2012) The effect of different dosing regimens of levodopa\/carbidopa\/entacapone on plasma levodopa concentrations. Eur J Clin Pharmacol 68:281\u2013289","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"1567_CR30","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.3390\/cells12071012","volume":"12","author":"S Isik","year":"2023","unstructured":"Isik S, Yeman Kiyak B, Akbayir R et al (2023) Microglia mediated neuroinflammation in Parkinson\u2019s disease. Cells 12(7):1012","journal-title":"Cells"},{"key":"1567_CR31","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.pnpbp.2018.07.010","volume":"88","author":"L Jiang","year":"2019","unstructured":"Jiang L, Zhang H, Wang C et al (2019) Serum level of brain-derived neurotrophic factor in Parkinson\u2019s disease: a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 88:168\u2013174","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1567_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1742-2094-10-45","volume":"10","author":"A Kaizaki","year":"2013","unstructured":"Kaizaki A, Tien L-T, Pang Y et al (2013) Celecoxib reduces brain dopaminergic neuronaldysfunction, and improves sensorimotor behavioral performance in neonatal rats exposed to systemic lipopolysaccharide. J Neuroinflamm 10:1\u201314","journal-title":"J Neuroinflamm"},{"issue":"21","key":"1567_CR33","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1016\/j.lfs.2005.10.002","volume":"78","author":"H Maharaj","year":"2006","unstructured":"Maharaj H, Maharaj D, Daya S (2006) Acetylsalicylic acid and acetaminophen protect against MPP+-induced mitochondrial damage and superoxide anion generation. Life Sci 78(21):2438\u20132443","journal-title":"Life Sci"},{"issue":"1","key":"1567_CR34","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.parkreldis.2014.10.026","volume":"21","author":"P Mart\u00ednez-Mart\u00edn","year":"2015","unstructured":"Mart\u00ednez-Mart\u00edn P, Rodr\u00edguez-Bl\u00e1zquez C, Alvarez M et al (2015) Parkinson\u2019s disease severity levels and MDS-Unified Parkinson\u2019s Disease Rating Scale. Parkinsonism Relat Disord 21(1):50\u201354","journal-title":"Parkinsonism Relat Disord"},{"key":"1567_CR35","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.neuroscience.2017.12.046","volume":"372","author":"E Mhillaj","year":"2018","unstructured":"Mhillaj E, Morgese MG, Tucci P et al (2018) Celecoxib prevents cognitive impairment and neuroinflammation in soluble amyloid \u03b2-treated rats. Neuroscience 372:58\u201373","journal-title":"Neuroscience"},{"issue":"2","key":"1567_CR36","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/ana.410420212","volume":"42","author":"Y Miyoshi","year":"1997","unstructured":"Miyoshi Y, Zhang Z, Ovadia A et al (1997) Glial cell line-derived neurotrophic factor-levodopa interactions and reduction of side effects in parkinsonian monkeys. Ann Neurol 42(2):208\u2013214","journal-title":"Ann Neurol"},{"key":"1567_CR37","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.pbb.2018.05.007","volume":"170","author":"M Morales-Sosa","year":"2018","unstructured":"Morales-Sosa M, Orozco-Su\u00e1rez S, Vega-Garc\u00eda A et al (2018) Immunomodulatory effect of Celecoxib on HMGB1\/TLR4 pathway in a recurrent seizures model in immature rats. Pharmacol Biochem Behav 170:79\u201386","journal-title":"Pharmacol Biochem Behav"},{"issue":"1","key":"1567_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0086806","volume":"9","author":"I Novakova","year":"2014","unstructured":"Novakova I, Subileau E-A, Toegel S et al (2014) Transport rankings of non-steroidal antiinflammatory drugs across blood-brain barrier in vitro models. PLoS ONE 9(1):e86806","journal-title":"PLoS ONE"},{"issue":"5","key":"1567_CR39","first-page":"477","volume":"22","author":"E Ramazani","year":"2019","unstructured":"Ramazani E, Tayarani-Najaran Z, Fereidoni M (2019) Celecoxib, indomethacin, and ibuprofen prevent 6-hydroxydopamine-induced PC12 cell death through the inhibition of NF\u03baB and SAPK\/JNK pathways. Iran J Basic Med Sci 22(5):477","journal-title":"Iran J Basic Med Sci"},{"issue":"12","key":"1567_CR40","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1212\/WNL.29.12.1584","volume":"29","author":"U Rinne","year":"1979","unstructured":"Rinne U, Molsa P (1979) Levodopa with benserazide or carbidopa in Parkinson disease. Neurology 29(12):1584\u20131589","journal-title":"Neurology"},{"key":"1567_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1742-2094-1-6","volume":"1","author":"R S\u00e1nchez-Pernaute","year":"2004","unstructured":"S\u00e1nchez-Pernaute R, Ferree A, Cooper O et al (2004) Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson\u2019s disease. J Neuroinflamm 1:1\u201311","journal-title":"J Neuroinflamm"},{"issue":"2","key":"1567_CR42","doi-asserted-by":"publisher","first-page":"e92178","DOI":"10.5812\/gct.92178","volume":"6","author":"M Sarbishegi","year":"2019","unstructured":"Sarbishegi M, Gorgich EAC (2019) The effects of Celecoxib on rotenone-induced rat model of Parkinson\u2019s disease: suppression of neuroinflammation and oxidative stress-mediated apoptosis. Gene Cell Tissue 6(2):e92178. https:\/\/doi.org\/10.5812\/gct.92178","journal-title":"Gene Cell Tissue"},{"issue":"1","key":"1567_CR43","first-page":"901902","volume":"2014","author":"T Shimada","year":"2014","unstructured":"Shimada T, Takemiya T, Sugiura H, Yamagata K (2014) Role of inflammatory mediators in the pathogenesis of epilepsy. Mediat Inflamm 2014(1):901902","journal-title":"Mediat Inflamm"},{"issue":"8","key":"1567_CR44","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.2174\/1570159X15666170510143821","volume":"16","author":"N Tambasco","year":"2018","unstructured":"Tambasco N, Romoli M, Calabresi P (2018) Levodopa in Parkinson\u2019s disease: current status and future developments. Curr Neuropharmacol 16(8):1239\u20131252","journal-title":"Curr Neuropharmacol"},{"issue":"2","key":"1567_CR45","doi-asserted-by":"publisher","first-page":"12812","DOI":"10.1080\/21655979.2021.2003661","volume":"12","author":"Q Wang","year":"2021","unstructured":"Wang Q, Chen Q, Sui J et al (2021) Celecoxib prevents tumor necrosis factor-\u03b1 (TNF-\u03b1)-induced cellular senescence in human chondrocytes. Bioengineered 12(2):12812\u201312820","journal-title":"Bioengineered"},{"key":"1567_CR46","first-page":"1","volume":"2019","author":"P-C Wei","year":"2019","unstructured":"Wei P-C, Lee-Chen G-J, Chen C-M et al (2019) Neuroprotection of indole-derivative compound NC001-8 by the regulation of the NRF2 pathway in Parkinson\u2019s disease cell models. Oxid Med Cell Longev 2019:1\u201315","journal-title":"Oxid Med Cell Longev"},{"key":"1567_CR47","first-page":"1","volume":"2016","author":"L Xu","year":"2016","unstructured":"Xu L, Pu J (2016) Alpha-synuclein in Parkinson\u2019s disease: from pathogenetic dysfunction to potential clinical application. Parkinson\u2019s Dis 2016:1\u201310","journal-title":"Parkinson\u2019s Dis"},{"key":"1567_CR48","doi-asserted-by":"publisher","first-page":"4754","DOI":"10.1007\/s12035-015-9355-3","volume":"53","author":"T Yagami","year":"2016","unstructured":"Yagami T, Koma H, Yamamoto Y (2016) Pathophysiological roles of cyclooxygenases and prostaglandins in the central nervous system. Mol Neurobiol 53:4754\u20134771","journal-title":"Mol Neurobiol"},{"key":"1567_CR49","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s12031-017-0922-0","volume":"62","author":"Y Yang","year":"2017","unstructured":"Yang Y, Gao L (2017) Celecoxib alleviates memory deficits by downregulation of COX-2 expression and upregulation of the BDNF-TrkB signaling pathway in a diabetic rat model. J Mol Neurosci 62:188\u2013198","journal-title":"J Mol Neurosci"},{"issue":"1","key":"1567_CR50","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jphs.2021.10.004","volume":"148","author":"Y Yoshioka","year":"2022","unstructured":"Yoshioka Y, Sugino Y, Yamamuro A et al (2022) Dopamine inhibits the expression of proinflammatory cytokines of microglial cells through the formation of dopamine quinone in the mouse striatum. J Pharmacol Sci 148(1):41\u201350","journal-title":"J Pharmacol Sci"},{"issue":"12","key":"1567_CR51","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/nrn3114","volume":"12","author":"BV Zlokovic","year":"2011","unstructured":"Zlokovic BV (2011) Neurovascular pathways to neurodegeneration in Alzheimer\u2019s disease and other disorders. Nat Rev Neurosci 12(12):723\u2013738","journal-title":"Nat Rev Neurosci"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-024-01567-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-024-01567-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-024-01567-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T20:03:37Z","timestamp":1731441817000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-024-01567-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,28]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1567"],"URL":"https:\/\/doi.org\/10.1007\/s10787-024-01567-z","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,28]]},"assertion":[{"value":"15 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No conflict of interest is declared by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Written informed consent was obtained from every study subject. No consent for publication was necessary because no private data were used.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The Mansoura University Faculty of Medicine's Institutional Review Board gave its acceptance for this study. The study complied with the 1964 amendments to the Helsinki Declaration's ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}